Ashton Thomas Private Wealth LLC lessened its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 89.2% during the third quarter, Holdings Channel reports. The institutional investor owned 3,025 shares of the financial services provider’s stock after selling 25,029 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in iShares Biotechnology ETF were worth $637,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. Bell Investment Advisors Inc bought a new stake in iShares Biotechnology ETF in the third quarter worth about $29,000. Pension & Wealth Management Advisors Inc. acquired a new position in iShares Biotechnology ETF in the second quarter worth approximately $28,000. Provenance Wealth Advisors LLC bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at $35,000. Trust Co. of Vermont bought a new position in shares of iShares Biotechnology ETF in the second quarter valued at $44,000. Finally, GKV Capital Management Co. Inc. bought a new position in shares of iShares Biotechnology ETF in the first quarter valued at $49,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Up 0.4%
Shares of NASDAQ:IBB opened at $218.14 on Thursday. The stock has a fifty day moving average of $208.98 and a 200-day moving average of $186.54. iShares Biotechnology ETF has a one year low of $159.68 and a one year high of $222.29.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
